New eye drop trial aims to tame severe childhood eye allergy
NCT ID NCT07169695
Summary
This study aims to see if a new investigational eye drop called T1695 is as effective and safe as an existing standard treatment (ciclosporin) for children and teenagers with moderate to severe vernal keratoconjunctivitis (VKC), a severe form of seasonal eye allergy. It will involve about 120 participants aged 4 to 18 years old. The main goal is to compare how well each treatment reduces damage to the surface of the eye over 4 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE VERNAL KERATOCONJUNCTIVITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.